Evidence map›Paper›PMID 22099067›Full record

Trial reportRadiation oncology (London, England)2011

Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study.

Chiara Molinari, Michela Ballardini, Nazario Teodorani, Massimo Giannini, Wainer Zoli, Ermanno Emiliani, Enrico Lucci, Alessandro Passardi, Paola Rosetti, Luca Saragoni and 3 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Radiation oncology (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Chiara MolinariBiosciences Laboratories, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Michela Ballardini
Nazario Teodorani
Massimo Giannini
Wainer Zoli
Ermanno Emiliani
Enrico Lucci
Alessandro Passardi
Paola Rosetti
Luca Saragoni
Massimo Guidoboni
Dino Amadori
Daniele Calistri
I.R.C.C.S. Oasi Maria SS · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale G.B. Morgagni - L.Pierantoni · ITOspedale "Santa Maria delle Croci" di Ravenna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemoradiotherapy is the treatment of choice in advanced rectal cancer, even though there are many patients who will not benefit from it. There are still no effective methods for predicting which patients will respond or not. The present study aimed to define the genomic profile of rectal tumors and to identify alterations that are predictive of response in order to optimize therapeutic strategies.

methodsForty-eight candidates for neoadjuvant chemoradiotherapy were recruited and their pretherapy biopsies analyzed by array Comparative Genomic Hybridization (aCGH). Pathologic response was evaluated by tumor regression grade.

resultsBoth Hidden Markov Model and Smoothing approaches identified similar alterations, with a prevalence of DNA gains. Non responsive patients had a different alteration profile from responsive ones, with a higher number of genome changes mainly located on 2q21, 3q29, 7p22-21, 7q21, 7q36, 8q23-24, 10p14-13, 13q12, 13q31-34, 16p13, 17p13-12 and 18q23 chromosomal regions.

conclusionsThis exploratory study suggests that an in depth characterization of chromosomal alterations by aCGH would provide useful predictive information on response to neoadjuvant chemoradiotherapy and could help to optimize therapy in rectal cancer patients.The data discussed in this study are available on the NCBI Gene Expression Omnibus [GEO: GSE25885].

Indexed as

Chemoradiotherapy, AdjuvantNeoadjuvant TherapyAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorCluster AnalysisComparative Genomic HybridizationFemaleFluorouracilHumansImmunohistochemistryMaleMiddle AgedRectal NeoplasmsAntineoplastic AgentsBiomarkers, TumorFluorouracil

Identifiers

PMID22099067
PMCPMC3236016
OpenAlexW2159344928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.